Fibroblast activation protein-α, a stromal cell surface protease, shapes key features of cancer associated fibroblasts through proteome and degradome alterations

Molecular Oncology

Volumn 10, Issue 1, 2016, Pages 40-58

  Koczorowska, M M ^a   Tholen, S ^a   Bucher, F ^b   Lutz, L ^b   Kizhakkedathu, J N ^c   De Wever, O ^d   Wellner, U F ^e   Biniossek, M L ^a   Stahl, A ^b   Lassmann, S ^a,b,f   Schilling, O ^a,f  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d GHENT UNIVERSITY HOSPITAL   (Belgium)

^e Clinic for Surgery   (Germany)

^f GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Angiogenesis; CAFs; Degradome; FAP ; Secretome; TGF

Indexed keywords

AMINE; COLLAGEN; DEGRADOME; DIPEPTIDASE; PROTEIN DEGRADATION END PRODUCT; PROTEOME; SEPRASE; TRANSFORMING GROWTH FACTOR; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; GELATINASE; MEMBRANE PROTEIN; SERINE PROTEINASE; TUMOR MARKER; TUMOR PROTEIN;

ARTICLE; CANCER ASSOCIATED FIBROBLAST; CARBOXY TERMINAL SEQUENCE; CLINICAL ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; ENZYME ACTIVITY; EPITHELIUM CELL; EXTRACELLULAR MATRIX; FIBROBLAST; GAIN OF FUNCTION MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LOSS OF FUNCTION MUTATION; PHENOTYPE; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; PROTEOMICS; TUMOR SPHEROID; COLORECTAL TUMOR; METABOLISM; PATHOLOGY; PHYSIOLOGY; STROMA CELL; TUMOR CELL LINE;

BIOMARKERS, TUMOR; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; FIBROBLASTS; GELATINASES; HUMANS; MEMBRANE PROTEINS; NEOPLASM PROTEINS; PROTEOLYSIS; PROTEOME; SERINE ENDOPEPTIDASES; STROMAL CELLS; TRANSFORMING GROWTH FACTOR BETA;

EID: 84953367391     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2015.08.001     Document Type: Article

References (127)

1. Acharya P.S., Zukas A., et al. Fibroblast activation protein: a serine protease expressed at the remodeling interface in idiopathic pulmonary fibrosis. Hum. Pathol. 2006, 37(3):352-360.
2. Aertgeerts K., Levin I., et al. Structural and kinetic analysis of the substrate specificity of human fibroblast activation protein alpha. J. Biol. Chem. 2005, 280(20):19441-19444.
3. Aggarwal S., Brennen W.N., et al. Fibroblast activation protein peptide substrates identified from human collagen I derived gelatin cleavage sites. Biochemistry 2008, 47(3):1076-1086.
4. Aoyama A., Chen W.T. A 170-kDa membrane-bound protease is associated with the expression of invasiveness by human malignant melanoma cells. Proc. Natl. Acad. Sci. U. S. A. 1990, 87(21):8296-8300.
5. Ariga N., Sato E., et al. Stromal expression of fibroblast activation protein/seprase, a cell membrane serine proteinase and gelatinase, is associated with longer survival in patients with invasive ductal carcinoma of breast. Int. J. Cancer 2001, 95(1):67-72.
6. Augoff K., Hryniewicz-Jankowska A., et al. Upregulated expression and activation of membrane associated proteases in esophageal squamous cell carcinoma. Oncol. Rep. 2014, 31(6):2820-2826.
7. Augsten M. Cancer-associated fibroblasts as another polarized cell type of the tumor microenvironment. Front. Oncol. 2014, 4:62.
8. Bae S., Park C.W., et al. Fibroblast activation protein alpha identifies mesenchymal stromal cells from human bone marrow. Br. J. Haematol. 2008, 142(5):827-830.
9. Bell E., Ivarsson B., et al. Production of a tissue-like structure by contraction of collagen lattices by human fibroblasts of different proliferative potential in vitro. Proc. Natl. Acad. Sci. U. S. A. 1979, 76(3):1274-1278.
10. Bildt M.M., Bloemen M., et al. Matrix metalloproteinase inhibitors reduce collagen gel contraction and alpha-smooth muscle actin expression by periodontal ligament cells. J. Periodontal Res. 2009, 44(2):266-274.
11. Biniossek M.L., Nagler D.K., et al. Proteomic identification of protease cleavage sites characterizes prime and non-prime specificity of cysteine cathepsins B, L, and S. J. Proteome Res. 2011, 10(12):5363-5373.
12. Bremnes R.M., Donnem T., et al. The role of tumor stroma in cancer progression and prognosis: emphasis on carcinoma-associated fibroblasts and non-small cell lung cancer. J. Thorac. Oncol. 2011, 6(1):209-217.
13. Brennen W.N., Denmeade S.R., et al. Mesenchymal stem cells as a vector for the inflammatory prostate microenvironment. Endocr. Relat. Cancer 2013, 20(5):R269-R290.
14. Brennen W.N., Rosen D.M., et al. Targeting carcinoma-associated fibroblasts within the tumor stroma with a fibroblast activation protein-activated prodrug. J. Natl. Cancer Inst. 2012, 104(17):1320-1334.
15. Brokopp C.E., Schoenauer R., et al. Fibroblast activation protein is induced by inflammation and degrades type I collagen in thin-cap fibroatheromata. Eur. Heart J. 2011, 32(21):2713-2722.
16. Buehler A., Sitaras N., et al. Semaphorin 3F forms an anti-angiogenic barrier in outer retina. FEBS Lett. 2013, 587(11):1650-1655.
17. Cao Y. Tumor angiogenesis and molecular targets for therapy. Front. Biosci. (Landmark Ed.) 2009, 14:3962-3973.
18. Cheng J.D., Dunbrack R.L., et al. Promotion of tumor growth by murine fibroblast activation protein, a serine protease, in an animal model. Cancer Res. 2002, 62(16):4767-4772.
19. Cheng J.D., Valianou M., et al. Abrogation of fibroblast activation protein enzymatic activity attenuates tumor growth. Mol. Cancer Ther. 2005, 4(3):351-360.
20. Christiansen V.J., Jackson K.W., et al. Effect of fibroblast activation protein and alpha2-antiplasmin cleaving enzyme on collagen types I, III, and IV. Arch. Biochem. Biophys. 2007, 457(2):177-186.
21. Cohen S.J., Alpaugh R.K., et al. Fibroblast activation protein and its relationship to clinical outcome in pancreatic adenocarcinoma. Pancreas 2008, 37(2):154-158.
22. Coussens L.M., Fingleton B., et al. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 2002, 295(5564):2387-2392.
23. Craig R., Beavis R.C. TANDEM: matching proteins with tandem mass spectra. Bioinformatics 2004, 20(9):1466-1467.
24. Daniels J.T., Cambrey A.D., et al. Matrix metalloproteinase inhibition modulates fibroblast-mediated matrix contraction and collagen production in vitro. Invest. Ophthalmol. Vis. Sci. 2003, 44(3):1104-1110.
25. De Bock M., Vandenbroucke R.E., et al. A new angle on blood-CNS interfaces: a role for connexins?. FEBS Lett. 2014, 588(8):1259-1270.
26. Duluc C., Moatassim-Billah S., et al. Pharmacological targeting of the protein synthesis mTOR/4E-BP1 pathway in cancer-associated fibroblasts abrogates pancreatic tumour chemoresistance. EMBO Mol. Med. 2015 Apr 1, 7(6):735-753.
27. Edosada C.Y., Quan C., et al. Peptide substrate profiling defines fibroblast activation protein as an endopeptidase of strict Gly(2)-Pro(1)-cleaving specificity. FEBS Lett. 2006, 580(6):1581-1586.
28. Edosada C.Y., Quan C., et al. Selective inhibition of fibroblast activation protein protease based on dipeptide substrate specificity. J. Biol. Chem. 2006, 281(11):7437-7444.
29. Fang Q., Liu X., et al. Thrombin induces collagen gel contraction partially through PAR1 activation and PKC-epsilon. Eur. Respir. J. 2004, 24(6):918-924.
30. Fortelny N., Cox J.H., et al. Network analyses reveal pervasive functional regulation between proteases in the human protease web. PLoS Biol. 2014, 12(5):e1001869.
31. Franceschini A., Szklarczyk D., et al. STRING v9.1: protein-protein interaction networks, with increased coverage and integration. Nucleic Acids Res. 2013, 41(Database issue):D808-D815.
32. Garin-Chesa P., Old L.J., et al. Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers. Proc. Natl. Acad. Sci. U. S. A. 1990, 87(18):7235-7239.
33. Ghersi G., Dong H., et al. Regulation of fibroblast migration on collagenous matrix by a cell surface peptidase complex. J. Biol. Chem. 2002, 277(32):29231-29241.
34. Gonda T.A., Varro A., et al. Molecular biology of cancer-associated fibroblasts: can these cells be targeted in anti-cancer therapy?. Semin. Cell Dev. Biol. 2010, 21(1):2-10.
35. Gottschalk S., Yu F., et al. A vaccine that co-targets tumor cells and cancer associated fibroblasts results in enhanced antitumor activity by inducing antigen spreading. PLoS One 2013, 8(12):e82658.
36. Hamson E.J., Keane F.M., et al. Understanding fibroblast activation protein (FAP): substrates, activities, expression and targeting for cancer therapy. Proteomics Clin. Appl. 2014, 8(5-6):454-463.
37. Han D.K., Eng J., et al. Quantitative profiling of differentiation-induced microsomal proteins using isotope-coded affinity tags and mass spectrometry. Nat. Biotechnol. 2001, 19(10):946-951.
38. Han Y., Zhang Y., et al. Molecular mechanism underlying the tumor-promoting functions of carcinoma-associated fibroblasts. Tumour Biol. 2015 Mar, 36(3):1385-1394.
39. Henry L.R., Lee H.O., et al. Clinical implications of fibroblast activation protein in patients with colon cancer. Clin. Cancer Res. 2007, 13(6):1736-1741.
40. Herz C., Schlurmann F., et al. Occurrence of Aurora A positive multipolar mitoses in distinct molecular classes of colorectal carcinomas and effect of Aurora A inhibition. Mol. Carcinog. 2012, 51(9):696-710.
41. Huang C.H., Suen C.S., et al. Cleavage-site specificity of prolyl endopeptidase FAP investigated with a full-length protein substrate. J. Biochem. 2011, 149(6):685-692.
42. Huang Y., Simms A.E., et al. Fibroblast activation protein-alpha promotes tumor growth and invasion of breast cancer cells through non-enzymatic functions. Clin. Exp. Metastasis 2011, 28(6):567-579.
43. Huang Y., Wang S., et al. Seprase promotes rapid tumor growth and increased microvessel density in a mouse model of human breast cancer. Cancer Res. 2004, 64(8):2712-2716.
44. Huber M.A., Kraut N., et al. Fibroblast activation protein: differential expression and serine protease activity in reactive stromal fibroblasts of melanocytic skin tumors. J. Invest. Dermatol. 2003, 120(2):182-188.
45. Jambunathan K., Watson D.S., et al. Comparative analysis of the substrate preferences of two post-proline cleaving endopeptidases, prolyl oligopeptidase and fibroblast activation protein alpha. FEBS Lett. 2012, 586(16):2507-2512.
46. Jansen K., Heirbaut L., et al. Extended structure-activity relationship and pharmacokinetic investigation of (4-quinolinoyl)glycyl-2-cyanopyrrolidine inhibitors of fibroblast activation protein (FAP). J. Med. Chem. 2014, 57(7):3053-3074.
47. Jung Y., Kim J.K., et al. Recruitment of mesenchymal stem cells into prostate tumours promotes metastasis. Nat. Commun. 2013, 4:1795.
48. Kakarla S., Song X.T., et al. Cancer-associated fibroblasts as targets for immunotherapy. Immunotherapy 2012, 4(11):1129-1138.
49. Kalluri R., Zeisberg M. Fibroblasts in cancer. Nat. Rev. Cancer 2006, 6(5):392-401.
50. Keane F.M., Nadvi N.A., et al. Neuropeptide Y, B-type natriuretic peptide, substance P and peptide YY are novel substrates of fibroblast activation protein-alpha. FEBS J. 2011, 278(8):1316-1332.
51. Kelly T. Fibroblast activation protein-alpha and dipeptidyl peptidase IV (CD26): cell-surface proteases that activate cell signaling and are potential targets for cancer therapy. Drug Resist. Updat. 2005, 8(1-2):51-58.
52. Kern U., Wischnewski V., et al. Lysosomal protein turnover contributes to the acquisition of TGFbeta-1 induced invasive properties of mammary cancer cells. Mol. Cancer 2015, 14(1):39.
53. Kessenbrock K., Plaks V., et al. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 2010, 141(1):52-67.
54. Kessner D., Chambers M., et al. ProteoWizard: open source software for rapid proteomics tools development. Bioinformatics 2008, 24(21):2534-2536.
55. Kidd S., Spaeth E., et al. Origins of the tumor microenvironment: quantitative assessment of adipose-derived and bone marrow-derived stroma. PLoS One 2012, 7(2):e30563.
56. Kim G.J., Rhee H., et al. Increased expression of CCN2, epithelial membrane antigen, and fibroblast activation protein in hepatocellular carcinoma with fibrous stroma showing aggressive behavior. PLoS One 2014, 9(8):e105094.
57. Kim W., Barron D.A., et al. RUNX1 is essential for mesenchymal stem cell proliferation and myofibroblast differentiation. Proc. Natl. Acad. Sci. U. S. A. 2014, 111(46):16389-16394.
58. Kleifeld O., Doucet A., et al. Isotopic labeling of terminal amines in complex samples identifies protein N-termini and protease cleavage products. Nat. Biotechnol. 2010, 28(3):281-288.
59. Kraman M., Bambrough P.J., et al. Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha. Science 2010, 330(6005):827-830.
60. Kumar S., Weaver V.M. Mechanics, malignancy, and metastasis: the force journey of a tumor cell. Cancer Metastasis Rev. 2009, 28(1-2):113-127.
61. Lai Z.W., Petrera A., et al. Protein amino-terminal modifications and proteomic approaches for N-terminal profiling. Curr. Opin. Chem. Biol. 2015, 24:71-79.
62. Lassmann S., Danciu M., et al. Aurora A is differentially expressed and regulated in chromosomal and microsatellite instable sporadic colorectal cancers. Mod. Pathol. 2009, 22(10):1385-1397.
63. Lee H.O., Mullins S.R., et al. FAP-overexpressing fibroblasts produce an extracellular matrix that enhances invasive velocity and directionality of pancreatic cancer cells. BMC Cancer 2011, 11:245.
64. Lee K.N., Jackson K.W., et al. Antiplasmin-cleaving enzyme is a soluble form of fibroblast activation protein. Blood 2006, 107(4):1397-1404.
65. Lee K.N., Jackson K.W., et al. Using substrate specificity of antiplasmin-cleaving enzyme for fibroblast activation protein inhibitor design. Biochemistry 2009, 48(23):5149-5158.
66. Li X.J., Zhang H., et al. Automated statistical analysis of protein abundance ratios from data generated by stable-isotope dilution and tandem mass spectrometry. Anal. Chem. 2003, 75(23):6648-6657.
67. Loeffler M., Kruger J.A., et al. Targeting tumor-associated fibroblasts improves cancer chemotherapy by increasing intratumoral drug uptake. J. Clin. Invest. 2006, 116(7):1955-1962.
68. Lunardi S., Muschel R.J., et al. The stromal compartments in pancreatic cancer: are there any therapeutic targets?. Cancer Lett. 2014, 343(2):147-155.
69. Martens L., Vandekerckhove J., et al. DBToolkit: processing protein databases for peptide-centric proteomics. Bioinformatics 2005, 21(17):3584-3585.
70. Martin P. Wound healing-aiming for perfect skin regeneration. Science 1997, 276(5309):75-81.
71. Mathew S., Scanlan M.J., et al. The gene for fibroblast activation protein alpha (FAP), a putative cell surface-bound serine protease expressed in cancer stroma and wound healing, maps to chromosome band 2q23. Genomics 1995, 25(1):335-337.
72. Mauer J., Denson J.L., et al. Versatile functions for IL-6 in metabolism and cancer. Trends Immunol. 2015, 36(2):92-101.
73. Mhawech-Fauceglia P., Yan L., et al. Stromal expression of fibroblast activation protein alpha (FAP) predicts platinum resistance and shorter recurrence in patients with epithelial ovarian cancer. Cancer Microenviron. 2015 Apr, 8(1):23-31.
74. Ming J.E., Cernetti C., et al. Interleukin 6 is the principal cytolytic T lymphocyte differentiation factor for thymocytes in human leukocyte conditioned medium. J. Mol. Cell. Immunol. 1989, 4(4):203-211. (discussion 211-202).
75. Mishra P.J., Mishra P.J., et al. Carcinoma-associated fibroblast-like differentiation of human mesenchymal stem cells. Cancer Res. 2008, 68(11):4331-4339.
76. Montesano R., Orci L. Transforming growth factor beta stimulates collagen-matrix contraction by fibroblasts: implications for wound healing. Proc. Natl. Acad. Sci. U. S. A. 1988, 85(13):4894-4897.
77. Nagase H., Woessner J.F. Matrix metalloproteinases. J. Biol. Chem. 1999, 274(31):21491-21494.
78. Narra K., Mullins S.R., et al. Phase II trial of single agent Val-boroPro (Talabostat) inhibiting fibroblast activation protein in patients with metastatic colorectal cancer. Cancer Biol. Ther. 2007, 6(11):1691-1699.
79. Nesvizhskii A.I., Keller A., et al. A statistical model for identifying proteins by tandem mass spectrometry. Anal. Chem. 2003, 75(17):4646-4658.
80. Niedermeyer J., Garin-Chesa P., et al. Expression of the fibroblast activation protein during mouse embryo development. Int. J. Dev. Biol. 2001, 45(2):445-447.
81. Niedermeyer J., Kriz M., et al. Targeted disruption of mouse fibroblast activation protein. Mol. Cell. Biol. 2000, 20(3):1089-1094.
82. Olsen J.V., Ong S.E., et al. Trypsin cleaves exclusively C-terminal to arginine and lysine residues. Mol. Cell. Proteomics 2004, 3(6):608-614.
83. Ostermann E., Garin-Chesa P., et al. Effective immunoconjugate therapy in cancer models targeting a serine protease of tumor fibroblasts. Clin. Cancer Res. 2008, 14(14):4584-4592.
84. Overall C.M., Kleifeld O. Tumour microenvironment - opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat. Rev. Cancer 2006, 6(3):227-239.
85. Overall C.M., Lopez-Otin C. Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat. Rev. Cancer 2002, 2(9):657-672.
86. Ozdemir B.C., Pentcheva-Hoang T., et al. Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. Cancer Cell 2014, 25(6):719-734.
87. Park J.E., Lenter M.C., et al. Fibroblast activation protein, a dual specificity serine protease expressed in reactive human tumor stromal fibroblasts. J. Biol. Chem. 1999, 274(51):36505-36512.
88. Patel S., Ngounou Wetie A.G., et al. Cancer secretomes and their place in supplementing other hallmarks of cancer. Adv. Exp. Med. Biol. 2014, 806:409-442.
89. Patsouras D., Papaxoinis K., et al. Fibroblast activation protein and its prognostic significance in correlation with vascular endothelial growth factor in pancreatic adenocarcinoma. Mol. Med. Rep. 2015 Jun, 11(6):4585-4590.
90. Paunescu V., Bojin F.M., et al. Tumour-associated fibroblasts and mesenchymal stem cells: more similarities than differences. J. Cell. Mol. Med. 2011, 15(3):635-646.
91. Pedrioli P.G., Eng J.K., et al. A common open representation of mass spectrometry data and its application to proteomics research. Nat. Biotechnol. 2004, 22(11):1459-1466.
92. Pineiro-Sanchez M.L., Goldstein L.A., et al. Identification of the 170-kDa melanoma membrane-bound gelatinase (seprase) as a serine integral membrane protease. J. Biol. Chem. 1997, 272(12):7595-7601.
93. Provenzano P.P., Inman D.R., et al. Collagen density promotes mammary tumor initiation and progression. BMC Med. 2008, 6:11.
94. Radisky E.S., Radisky D.C. Stromal induction of breast cancer: inflammation and invasion. Rev. Endocr. Metab. Disord. 2007, 8(3):279-287.
95. Ramirez-Montagut T., Blachere N.E., et al. FAPalpha, a surface peptidase expressed during wound healing, is a tumor suppressor. Oncogene 2004, 23(32):5435-5446.
96. Rettig W.J., Garin-Chesa P., et al. Cell-surface glycoproteins of human sarcomas: differential expression in normal and malignant tissues and cultured cells. Proc. Natl. Acad. Sci. U. S. A. 1988, 85(9):3110-3114.
97. Rettig W.J., Garin-Chesa P., et al. Regulation and heteromeric structure of the fibroblast activation protein in normal and transformed cells of mesenchymal and neuroectodermal origin. Cancer Res. 1993, 53(14):3327-3335.
98. Roberts E.W., Deonarine A., et al. Depletion of stromal cells expressing fibroblast activation protein-alpha from skeletal muscle and bone marrow results in cachexia and anemia. J. Exp. Med. 2013, 210(6):1137-1151.
99. Rogers L.D., Overall C.M. Proteolytic post-translational modification of proteins: proteomic tools and methodology. Mol. Cell. Proteomics 2013, 12(12):3532-3542.
100. Santos A.M., Jung J., et al. Targeting fibroblast activation protein inhibits tumor stromagenesis and growth in mice. J. Clin. Invest. 2009, 119(12):3613-3625.
101. Sato H., Takino T. Coordinate action of membrane-type matrix metalloproteinase-1 (MT1-MMP) and MMP-2 enhances pericellular proteolysis and invasion. Cancer Sci. 2010, 101(4):843-847.
102. Scanlan M.J., Raj B.K., et al. Molecular cloning of fibroblast activation protein alpha, a member of the serine protease family selectively expressed in stromal fibroblasts of epithelial cancers. Proc. Natl. Acad. Sci. U. S. A. 1994, 91(12):5657-5661.
103. Schilling O., Auf dem Keller U., et al. Factor Xa subsite mapping by proteome-derived peptide libraries improved using WebPICS, a resource for proteomic identification of cleavage sites. Biol. Chem. 2011, 392(11):1031-1037.
104. Schilling O., Findeisen P. Proteases and disease. Proteomics Clin. Appl. 2014, 8(5-6):296-298.
105. Schilling O., Huesgen P.F., et al. Characterization of the prime and non-prime active site specificities of proteases by proteome-derived peptide libraries and tandem mass spectrometry. Nat. Protoc. 2011, 6(1):111-120.
106. Schilling O., Overall C.M. Proteome-derived, database-searchable peptide libraries for identifying protease cleavage sites. Nat. Biotechnol. 2008, 26(6):685-694.
107. Schneider C.A., Rasband W.S., et al. NIH Image to ImageJ: 25 years of image analysis. Nat. Methods 2012, 9(7):671-675.
108. Scott A.M., Wiseman G., et al. A phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer. Clin. Cancer Res. 2003, 9(5):1639-1647.
109. Shahinian H., Loessner D., et al. Secretome and degradome profiling shows that Kallikrein-related peptidases 4, 5, 6, and 7 induce TGFbeta-1 signaling in ovarian cancer cells. Mol. Oncol. 2014, 8(1):68-82.
110. Shahinian H., Tholen S., et al. Proteomic identification of protease cleavage sites: cell-biological and biomedical applications. Expert Rev. Proteomics 2013, 10(5):421-433.
111. Shan L.H., Sun W.G., et al. Roles of fibroblasts from the interface zone in invasion, migration, proliferation and apoptosis of gastric adenocarcinoma. J. Clin. Pathol. 2012, 65(10):888-895.
112. Shangguan L., Ti X., et al. Inhibition of TGF-beta/Smad signaling by BAMBI blocks differentiation of human mesenchymal stem cells to carcinoma-associated fibroblasts and abolishes their protumor effects. Stem Cells 2012, 30(12):2810-2819.
113. Sijare F., Geissler A.L., et al. Aurora B expression and histone variant H1.4S27 phosphorylation are no longer coordinated during metaphase in aneuploid colorectal carcinomas. Virchows Arch. 2015 May, 466(5):503-515.
114. Soneoka Y., Cannon P.M., et al. A transient three-plasmid expression system for the production of high titer retroviral vectors. Nucleic Acids Res. 1995, 23(4):628-633.
115. Taddei M.L., Giannoni E., et al. Microenvironment and tumor cell plasticity: an easy way out. Cancer Lett. 2013, 341(1):80-96.
116. Tholen S., Biniossek M.L., et al. Double deficiency of cathepsins B and L results in massive secretome alterations and suggests a degradative cathepsin-MMP axis. Cell. Mol. Life Sci. 2014, 71(5):899-916.
117. Tholen S., Biniossek M.L., et al. Deletion of cysteine cathepsins B or L yields differential impacts on murine skin proteome and degradome. Mol. Cell. Proteomics 2013, 12(3):611-625.
118. Tran E., Chinnasamy D., et al. Immune targeting of fibroblast activation protein triggers recognition of multipotent bone marrow stromal cells and cachexia. J. Exp. Med. 2013, 210(6):1125-1135.
119. Uniprot Consortium Update on activities at the Universal Protein Resource (UniProt) in 2013. Nucleic Acids Res 2013, 41(2013):D43-D47.
120. Van Damme J., Van Beeumen J., et al. Separation and comparison of two monokines with lymphocyte-activating factor activity: IL-1 beta and hybridoma growth factor (HGF). Identification of leukocyte-derived HGF as IL-6. J. Immunol. 1988, 140(5):1534-1541.
121. Van Hoorde L., Braet K., et al. The N-cadherin/catenin complex in colon fibroblasts and myofibroblasts. Cell Adhes. Commun. 1999, 7(2):139-150.
122. Wang X.M., Yao T.W., et al. Fibroblast activation protein and chronic liver disease. Front. Biosci. 2008, 13:3168-3180.
123. Yang L., Ma L., et al. Over-expression of fibroblast activation protein alpha increases tumor growth in xenografts of ovarian cancer cells. Acta Biochim. Biophys. Sin. (Shanghai) 2013, 45(11):928-937.
124. Yang W., Han W., et al. Fibroblast activation protein-alpha promotes ovarian cancer cell proliferation and invasion via extracellular and intracellular signaling mechanisms. Exp. Mol. Pathol. 2013, 95(1):105-110.
125. Zhang J., Liu J. Tumor stroma as targets for cancer therapy. Pharmacol. Ther. 2013, 137(2):200-215.
126. Zhang J., Valianou M., et al. Identification of inhibitory scFv antibodies targeting fibroblast activation protein utilizing phage display functional screens. FASEB J. 2013, 27(2):581-589.
127. Zi F., He J., et al. Fibroblast activation protein alpha in tumor microenvironment: recent progression and implications (review). Mol. Med. Rep. 2015, 11(5):3203-3211.